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disability. METHODS: Randomly selected Athens Stroke Regis-
try ischaemic stroke patients, 18 years of age or older, still alive
at least 90 days post stroke and willing to attend a study visit
were administered a 30-day retrospective resource use question-
naire, the EQ-5D, the Stroke Impact Scale (SIS-16), Modiﬁed
Rankin Scale (mRS), and Barthel Index; caregivers reported
resource use and hours of informal care. Stroke history was
obtained from registry records. RESULTS: A total of 365 sub-
jects (65% male; mean age 71 years) were enrolled at a mean
time post stroke of 2.8 years (min 0.3–max 14.2 years). At the
study visit, post-stroke disability was evenly distributed (mRS:
0 = 17%; 1 = 17%; 2 = 17%; 3 = 17%; 4 = 16%; 5 = 16%);
98% (n = 357) of patients were residing at home, but 57%
(n = 205) of these needed help with ADLs. Of the 2% (n = 8)
who resided in a long-term care facility, all had severe disability
(mRS 3,4,5). Mean informal care time received by patients with
severe disability over the previous 7 days by all caregivers in the
family was 145.4 (SD = 67.6) hours; patients with mild/moderate
(mRS 0,1,2) disability received 52.6 (SD = 44.2) hours
(p < 0.001). CONCLUSIONS: Despite moderate or severe dis-
ability in a substantial proportion of this Greek cohort, most of
these post-stroke patients were cared for by their caregivers at
home. Post-stroke impairment remains an important determi-
nant of caregiver burden well beyond the acute care period,
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OBJECTIVES: In patients with acute coronary syndromes
(ACS), continued treatment with thienopyridine regimens has
been associated with fewer major adverse cardiac events. In the
TRITON-TIMI 38 trial, prasugrel was compared to clopidogrel
in ACS patients undergoing percutaneous coronary intervention
(PCI) resulting in a 19% reduction in cardiovascular death, myo-
cardial infarction, or stroke, but an increase in TIMI deﬁned
bleeding (10.9% vs 7.9%, p < 0.001). The impact of these com-
plications on medication persistence and adherence is unknown.
The objective of this study was to compare persistence and
adherence of clopidogrel and prasugrel in TRITON TIMI-38.
METHODS: TRITON TIMI-38 was a double-blind, random-
ized, controlled trial which enrolled 13,608 patients with ACS
and planned PCI. Of the 13,608 patients enrolled, 13,457
patients received at least one dose of study drug and were evalu-
ated for this study. Patients treated with prasugrel (N = 6,741) or
clopidogrel (N = 67,16) were followed for up to 15 months.
Adherence was calculated using the medication possession ratio
(MPR), the total days with medication divided by total days in
the study. Persistence was measured as the time from random-
ization to the ﬁrst gap of >14 days between exhausting the
supplied medication and ﬁlling the next prescription. Sensitivity
analyses using gaps of 7 and 30 days were performed. Clopi-
dogrel and prasugrel adherence and persistence were compared
using multivariate linear regression, controlling for demograph-
ics and illness history. Robustness of results was examined using
alternative modeling. RESULTS: A total of 17.6% of patients
prematurely discontinued study drug (prasugrel, 17.9% vs. clo-
pidogrel, 17.3%, p = 0.382). The MPR for prasugrel (0.96) and
clopidogrel (0.96) were similar (p = 0.801). Similar persistence
levels between prasugrel-treated patients and clopidogrel-treated
patients were observed using the 14-day gap (319 vs. 322 days,
p = 0.296). Sensitivity analysis using 7-day and 30-day gaps
conﬁrmed these ﬁndings. Study drug was discontinued for a
hemorrhagic adverse event (AE) in 2.5% of prasugrel patients
compared to 1.4% of clopidogrel patients (p < 0.001) and
stopped for a non-hemorrhagic AE in 4.6% v 5.0% (p = 0.372).
CONCLUSIONS: Despite an increase in TIMI deﬁned bleeding
and an increased rate of discontinuation of study drug for a
hemorrhagic event with prasugrel, similar levels of adherence
and persistence were observed for prasugrel-and clopidogrel-
treated ACS patients with PCI in TRITON TIMI-38. Further
study will be necessary to determine whether these results can be
replicated outside of the clinical trial setting.
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OBJECTIVES: This study examined persistence with amio-
darone and sotalol and the effect of stopping treatment on atrial
ﬁbrillation (AF)-related hospitalizations and cardioversions.
METHODS: A cohort of patients with a diagnosis of AF
recorded between 1999 and 2005 was assembled from the
PHARMetrics® database. The cohort included treatment-naïve
adults aged 40 years or older who established treatment with
amiodarone or sotalol (at least two consecutive prescriptions).
Discontinuation was deﬁned as a gap in availability of the index
treatment lasting at least 60 days, or one reﬁll period plus one
month, whichever was longer. Patients were followed until out-
comes of interest or end of follow-up, deﬁned as end of admin-
istrative data, change in coverage, switching to or adding another
treatment, or restarting treatment after not persisting. The
impact of persistence on hospitalizations and on cardioversions
was assessed using Cox regression models with a time-dependent
indicator for persistence adjusting for baseline covariates.
RESULTS: Over a mean follow-up of 1.26 years of 8193 patients
(65% male, mean age 67 years), persistence with amiodarone
was 44% after one year and 60% with sotalol (median times: 9.4
vs. 19 months, respectively; p < 0.001). By the third year, only
20% were still on amiodarone and 30% on sotalol. The majority
of patients (62%) did not collect any prescription after discon-
tinuation. Of those who did, patients taking sotalol were more
likely to switch to or add another treatment, while patients on
amiodarone tended to restart on the same drug. Persistence was
associated with a decreased risk of cardioversions (hazard ratio,
HR = 0.37, 95%CI: 0.25–0.56), but only borderline with hospi-
talizations (HR = 0.86, 95%CI: 0.79–1.02). CONCLUSIONS:
Persistence with amiodarone or sotalol is generally poor, and
patients who discontinue treatment are unlikely to restart at a
later time. Stopping treatment was associated with increased
risk of cardioversions and a trend of increased AF-related
hospitalizations.
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